Stay updated with breaking news from Huck Institutes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Bill & Melinda Gates Foundation are awarding a $4.96 million grant to PlantVillage to help increase food production for smallholder farmers who face pests and disease of their crops across sub-Saharan Africa. The research project, called Delphi, will create a modeling platform that can be used by researchers globally to improve the speed and accuracy of efforts to identify emerging threats.
The Microbiome Center in the Huck Institutes of the Life Sciences at Penn State has announced its renaming to the One Health Microbiome Center, reflecting its collaborative culture and aspirations to write its next chapter in the booming study of microbial communities that live throughout the world's environments.
The 19 interdisciplinary research teams that received funding include more than 75 researchers who are affiliated with 10 colleges and research units across seven Penn State campuses.
The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model. Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu.
The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model. Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu.